Literature DB >> 31742994

Statistically Driven Metabolite and Lipid Profiling of Patients from the Undiagnosed Diseases Network.

Bobbie-Jo M Webb-Robertson, Kelly G Stratton, Jennifer E Kyle, Young-Mo Kim, Lisa M Bramer, Katrina M Waters, David M Koeller1, Thomas O Metz.   

Abstract

Advancements in molecular separations coupled with mass spectrometry have enabled metabolome analyses for clinical cohorts. A population of interest for metabolome profiling is patients with rare disease for which abnormal metabolic signatures may yield clues into the genetic basis, as well as mechanistic drivers of the disease and possible treatment options. We undertook the metabolome profiling of a large cohort of patients with mysterious conditions characterized through the Undiagnosed Diseases Network (UDN). Due to the size and enrollment procedures, collection of the metabolomes for UDN patients took place over 2 years. We describe the study designed to adjust for measurements collected over a long time scale and how this enabled statistical analyses to summarize the metabolome of individual patients. We demonstrate the removal of time-based batch effects, overall statistical characteristics of the UDN population, and two case studies of interest that demonstrate the utility of metabolome profiling for rare diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31742994      PMCID: PMC7183858          DOI: 10.1021/acs.analchem.9b03522

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  29 in total

Review 1.  Inherited metabolic rare disease.

Authors:  Teresa Pampols
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease.

Authors:  Rachel B Ramoni; John J Mulvihill; David R Adams; Patrick Allard; Euan A Ashley; Jonathan A Bernstein; William A Gahl; Rizwan Hamid; Joseph Loscalzo; Alexa T McCray; Vandana Shashi; Cynthia J Tifft; Anastasia L Wise
Journal:  Am J Hum Genet       Date:  2017-02-02       Impact factor: 11.025

3.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Authors:  Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork
Journal:  Per Med       Date:  2011-03       Impact factor: 2.512

4.  Comparing identified and statistically significant lipids and polar metabolites in 15-year old serum and dried blood spot samples for longitudinal studies.

Authors:  Jennifer E Kyle; Cameron P Casey; Kelly G Stratton; Erika M Zink; Young-Mo Kim; Xueyun Zheng; Matthew E Monroe; Karl K Weitz; Kent J Bloodsworth; Daniel J Orton; Yehia M Ibrahim; Ronald J Moore; Christine G Lee; Catherine Pedersen; Eric Orwoll; Richard D Smith; Kristin E Burnum-Johnson; Erin S Baker
Journal:  Rapid Commun Mass Spectrom       Date:  2017-03-15       Impact factor: 2.419

Review 5.  Metabolomics: a challenge for detecting and monitoring inborn errors of metabolism.

Authors:  Michele Mussap; Marco Zaffanello; Vassilios Fanos
Journal:  Ann Transl Med       Date:  2018-09

6.  Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism.

Authors:  Marcus J Miller; Adam D Kennedy; Andrea D Eckhart; Lindsay C Burrage; Jacob E Wulff; Luke A D Miller; Michael V Milburn; John A Ryals; Arthur L Beaudet; Qin Sun; V Reid Sutton; Sarah H Elsea
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

7.  Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies.

Authors:  Giovanna Capodivento; Davide Visigalli; Martina Garnero; Roberto Fancellu; Michela Demetra Ferrara; Abdul Basit; Zeeshan Hamid; Vito Paolo Pastore; Silvano Garibaldi; Andrea Armirotti; Gianluigi Mancardi; Carlo Serrati; Elisabetta Capello; Angelo Schenone; Lucilla Nobbio
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

8.  Metabolomics based markers predict type 2 diabetes in a 14-year follow-up study.

Authors:  Jun Liu; Sabina Semiz; Sven J van der Lee; Ashley van der Spek; Aswin Verhoeven; Jan B van Klinken; Eric Sijbrands; Amy C Harms; Thomas Hankemeier; Ko Willems van Dijk; Cornelia M van Duijn; Ayşe Demirkan
Journal:  Metabolomics       Date:  2017-07-28       Impact factor: 4.290

9.  LIQUID: an-open source software for identifying lipids in LC-MS/MS-based lipidomics data.

Authors:  Jennifer E Kyle; Kevin L Crowell; Cameron P Casey; Grant M Fujimoto; Sangtae Kim; Sydney E Dautel; Richard D Smith; Samuel H Payne; Thomas O Metz
Journal:  Bioinformatics       Date:  2017-06-01       Impact factor: 6.937

Review 10.  Integration of genomics and metabolomics for prioritization of rare disease variants: a 2018 literature review.

Authors:  Emma Graham; Jessica Lee; Magda Price; Maja Tarailo-Graovac; Allison Matthews; Udo Engelke; Jeffrey Tang; Leo A J Kluijtmans; Ron A Wevers; Wyeth W Wasserman; Clara D M van Karnebeek; Sara Mostafavi
Journal:  J Inherit Metab Dis       Date:  2018-05-02       Impact factor: 4.982

View more
  5 in total

1.  Rare disease care pathways in the EU: from odysseys and labyrinths towards highways.

Authors:  Birute Tumiene; Holm Graessner
Journal:  J Community Genet       Date:  2021-03-18

Review 2.  Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation.

Authors:  Ernesto S Nakayasu; Marina Gritsenko; Paul D Piehowski; Yuqian Gao; Daniel J Orton; Athena A Schepmoes; Thomas L Fillmore; Brigitte I Frohnert; Marian Rewers; Jeffrey P Krischer; Charles Ansong; Astrid M Suchy-Dicey; Carmella Evans-Molina; Wei-Jun Qian; Bobbie-Jo M Webb-Robertson; Thomas O Metz
Journal:  Nat Protoc       Date:  2021-07-09       Impact factor: 17.021

Review 3.  Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests.

Authors:  Florence Anne Castelli; Giulio Rosati; Christian Moguet; Celia Fuentes; Jose Marrugo-Ramírez; Thibaud Lefebvre; Hervé Volland; Arben Merkoçi; Stéphanie Simon; François Fenaille; Christophe Junot
Journal:  Anal Bioanal Chem       Date:  2021-08-25       Impact factor: 4.142

4.  LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease.

Authors:  Hoda Safari Yazd; Sina Feizbakhsh Bazargani; Christine A Vanbeek; Kelli King-Morris; Coy Heldermon; Mark S Segal; William L Clapp; Timothy J Garrett
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-11-26

Review 5.  A guide for the diagnosis of rare and undiagnosed disease: beyond the exome.

Authors:  Shruti Marwaha; Joshua W Knowles; Euan A Ashley
Journal:  Genome Med       Date:  2022-02-28       Impact factor: 15.266

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.